Improving the accuracy of cancer biomarker testing using advanced imaging techniques
Reproducible and Accurate PD-L1 Immunohistochemistry Biomarker Quantification Using Virtual Multiplex Immunofluorescence Restaining
This study is looking at a new way to check for a protein called PD-L1 in cancer patients to help doctors decide who might benefit from immunotherapy, making sure that patients get the right treatment without wasting money on options that won't work for them.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11018883 on NIH RePORTER |
What this research studies
This research focuses on enhancing the assessment of PD-L1 protein expression in cancer patients, which is crucial for determining their eligibility for immunotherapy treatments. By utilizing advanced multiplex immunofluorescence staining techniques, the study aims to provide more accurate and reproducible results compared to traditional methods. This approach seeks to reduce the variability in scoring by pathologists, thereby ensuring that patients receive appropriate treatment based on reliable biomarker evaluations. The goal is to identify patients who are unlikely to benefit from expensive immunotherapy, ultimately improving treatment outcomes and reducing unnecessary costs.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients being considered for immunotherapy who require accurate PD-L1 expression assessment.
Not a fit: Patients who do not have cancer or those whose treatment does not involve immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more precise patient selection for immunotherapy, improving treatment efficacy and reducing healthcare costs.
How similar studies have performed: Previous research has shown promising results with multiplex immunofluorescence techniques, indicating potential for significant advancements in biomarker quantification.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Nadeem, Saad — Sloan-Kettering Inst Can Research
- Study coordinator: Nadeem, Saad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.